Advirna is a biotechnology company developing innovative solutions for efficient delivery of oligonucleotides (Company Web Page, MirImmune, MAR 27, 2015, View Source [SID:1234502854]). Through a research and development agreement with Advirna, MirImmune gains access to sdRNA lead compounds for new checkpoint targets and novel types of sdRNA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!